In a few months time, those suffering from skin cancer may find an unlikely hero in their treatment regimen: herpes. A modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial. That means it's just waiting for a final okay from the FDA before the Amgen product can hit the market. The results of the trial were published Tuesday in Journal of Clinical Oncology.
In a study of 436 patients with inoperable melanoma, Talimogene Laherparepvec had 16.3 percent of patients showing results at the six-month mark, compared to 2.1 percent taking the control therapy. Some patients were continuing to respond to T-VEC three years later.
Patients with stage III and early stage IV melanoma treated with T-VEC (163 people in all) lived an average of 41 months. This compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy. Immunotherapy, where agents are used to boost a body's natural defense against a tumor, are already the best treatments against melanoma. But this is the first time a modified virus has been successful in carrying out that treatment.
Using a virus as a drug isn't a new idea. Phage therapy, where viruses that attack certain bacteria are used in place of antibiotics, is commonly used in Europe and on the rise in the United States. But cancer therapies like the one described in the new paper take things a step further, manipulating existing viruses to turn them into cancer-fighting tools.
Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research and head of the trial, has been working on this particular virus for about a decade. Before he signed onto the project, it was primarily being investigated as a breast cancer treatment. But Harrington brought head, neck, and skin cancer patients into the mix, and melanoma seemed to have the best responses of all.
Here's how T-VEC works: It starts with the herpes virus, which is magnificent at proliferating itself within cells and then causing them to burst (that's where the cold sores come from). But T-VEC has had two key genes removed. These keep it from replicating within healthy cells, which can quickly spot it because of the missing genes.
But cancer cells aren't as savvy, and T-VEC has its run of them. Meanwhile, T-VEC has also been modified to produce a molecule called GM-CSF, which serves as a red flag waved at the immune system.
So in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed — the tumor.
"This is a first in class agent, a brand new therapy," Harrington said. "But it's just the farthest along of what we hope will be many more."
Harrington expects the FDA to clear T-VEC within the year, and it could potentially be available to patients right away.
But there's more work to be done to determine just how T-VEC can fit into the cancer-treatment landscape. When the latest trial was started, Harrington explained, there was no standard of treatment for melanoma — so it's compared to a treatment that no one expected to outpace T-VEC. Now that other therapies — ones that target specific mutations in patients' cancer cells — are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.
"The next steps are exciting, and already underway," he said. "The next big frontier will be to combine this with existing immunotherapies. There's a strong rationale that other drugs on the market could act synogistically with ours."
Trials are also underway to determine how T-VEC might do with other cancers. In the meantime, other researchers will continue to crack the codes of other viruses to make them do our bidding.
The Washington Post
Wed May 27 2015
In a few months time, those suffering from skin cancer may find an unlikely hero in their treatment regimen: herpes.
ANALYSIS - World lags on 2030 nature goals headed into UN COP16 talks
A top concern for countries and companies is how to pay for conservation, with the COP16 talks aiming to develop new initiatives.
Situation in South China Sea safe, under control - Adly
Adly Zahari clarifies that reports of Chinese maritime assets near country's border mainly involve its Coast Guard, not its naval warships.
MOHE sets agenda to boost higher education cooperation ahead of ASEAN Chairmanship 2025
Datuk Seri Dr. Zambry said all higher education institutions must be involved to successfully implement the ASEAN chairmanship agenda.
King receives credentials of 12 foreign envoys to Malaysia
His Majesty Sultan Ibrahim welcomes nine new foreign envoys and appoints two Malaysian diplomats in a ceremony at Istana Negara.
Israel gives the US its demands for ending war in Lebanon, Axios reports
Israel demands IDF "active enforcement" to prevent Hezbollah from rearming and rebuilding military infrastructure near the border.
Indonesia's Prabowo swears in cabinet of over 100 ministers, deputies
Prabowo Subianto's cabinet has 48 ministries with over 100 ministers and deputies, including two re-appointments.
Freeze on foreign worker employment quota to continue - Saifuddin
Datuk Seri Saifuddin Nasution Ismail said as of Sept 15 the total number of foreign workers is nearing the stipulated ceiling.
King Charles and Queen Camilla visit Canberra on Australia tour
This is King Charles' first major foreign trip since being diagnosed with cancer in February.
Indonesia's Prabowo plans military academy retreat for new cabinet
The retreat is aimed at forming a bond between around 100 cabinet ministers and their deputies, according to migrant protection minister.
Four loan sharks held for alleged involvement in paint splashing, arson in six states
The syndicate is believed to have conducted illegal money-lending activities, involving loan sharks and online money-lending, police said.
China's PCT international patent applications top world for 5 consecutive years: WIPO chief
China has become the country with the most international patent applications, according to AIPPI President Shoichi Okuyama.
Charles Leclerc wins US Grand Prix; Max Verstappen 3rd after Norris penalty
Charles Leclerc also won the Monaco Grand Prix and Italian Grand Prix this year and sits third in the driver standings.
Australia's Qantas told to pay $114,000 to 3 sacked workers in landmark outsourcing case
Qantas claims the sackings were warranted as a cost-cutting measure during the COVID-19 pandemic.
After Sinwar's death, Israel aims to lock in strategic gains before US election
Israeli leaders are seeking to reshape regional landscape in Israel's favour and shield its borders from any future attacks, sources said.
Netanyahu told Trump Israel will make decisions based on its interests, PM's office says
Israel is pondering its military reaction to recent Iranian missile strikes.
Ringgit extends positive momentum to open higher against US dollar
The ringgit traded higher against the US Dollar in today's early session, driven by continued buying interest towards the local currency.
BHP faces $47 billion UK lawsuit over Brazilian dam collapse
More than 600,000 Brazilians, 46 local governments, and around 2,000 businesses are suing BHP over the collapse of the dam.
Trump hands out french fries in Pennsylvania, Harris visits Georgia churches
Both candidates were scrambling for votes in the most competitive states.
Brazil's Lula cancels BRICS trip after minor brain hemorrhage from fall
Lula "was advised to avoid long-distance air travel but is otherwise able to carry out his regular duties."
Lebanese flee as blasts hit Beirut, Israel warns of strikes on Hezbollah finance arm
On Sunday Israel said it hit Hezbollah's intelligence headquarters and an underground weapons workshop in Beirut.